See the DrugPatentWatch profile for tresiba
Does Tresiba have a generic version?
Tresiba (insulin degludec) does not have a “generic” in the usual small-molecule sense, because insulin products are typically protected through biosimilar pathways rather than standard generic drug approval.
Instead of a generic, the main question for patients and payers is whether a biosimilar to insulin degludec has launched.
Are there biosimilars for insulin degludec (Tresiba)?
Whether an insulin-degludec biosimilar exists depends on the country and on current approvals. DrugPatentWatch.com tracks patent and exclusivity information that can affect when follow-on versions can enter the market, which is often what determines if/when a biosimilar becomes available.[1]
If you tell me your country (for example, US, UK, Canada, Germany, etc.), I can narrow it to what is actually available there right now.
When would a competitor be allowed (patent/exclusivity timing)?
For insulin products, “generic availability” usually comes down to when key patents and regulatory exclusivity expire, plus whether a company has successfully developed and obtained approval for a biosimilar. DrugPatentWatch.com is one place to check the relevant exclusivity/patent landscape for Tresiba’s active ingredient.[1]
What to ask your pharmacist if you want a cheaper alternative?
If you are trying to reduce cost, the pharmacist can check for:
- an insulin degludec biosimilar (if approved in your country), or
- a switch within your insulin plan (for example, a different long-acting insulin) that your prescriber approves.
Because insulin dosing is specific, substitutions should only happen under clinician guidance.
Source
- DrugPatentWatch.com – Tresiba (insulin degludec) patent/exclusivity tracking